PubMed banner
PubMed Nucleotide Protein Genome Structure PopSet
 Search for
  Limits Preview/Index History Clipboard    
About Entrez
spacer gif
back to About Entrez
back to About Entrez

Entrez PubMed
Overview
Help | FAQ
New/Noteworthy

PubMed Services
Journal Browser
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Old PubMed

Related Resources
Order Documents
Grateful Med
Consumer Health
Clinical Alerts
ClinicalTrials.gov


Privacy Policy

   

1: Cancer Treat Rev 2000 Aug;26(4):269-286 Books

Monoclonal antibody therapy for solid tumors.

Green MC, Murray JL, Hortobagyi GN

The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, U.S.A.

[Record supplied by publisher]

Monoclonal antibody therapy for solid tumors has many theoretical attractions and a long history. Until recently, with the approval and widespread use of rituximab (Rituxan) and trastuzumab (Herceptin), monoclonal antibody therapy for tumors had not had significant success. This article reviews basic theories behind antibody development and their clinical implementation as treatment for solid tumors. Medline was searched for articles over the past 15 years dealing with laboratory and clinical applications of antibody therapy for solid tumors. In addition, American Society of Clinical Oncology (ASCO) abstracts from the past 3 years were reviewed to complement the Medline search. This article focuses on treatment for common solid tumors, including breast, colon and lung cancers. Copyright 2000 Harcourt Publishers Ltd.

PMID: 10913382